CME Corner

Active Programs

Improving Outcomes in Advanced Gastric Cancer: The Latest Updates in Treatment Strategies and Clinical Research

An estimated 26,370 Americans will be diagnosed with gastric cancer in 2016. Most patients with gastric cancer present with advanced or metastatic disease, for which the prognosis is poor. The 5-year survival rate of patients with all stages of gastric cancer in the United States is approximately 29% and drops into the single digits for patients with stage III or IV disease. However, recent advanc ...

  • Mobile + Online on QuantiaMD Mobile + Online on QuantiaMD

Multidisciplinary Care of Patients with Relapsed/Refractory Multiple Myeloma

The treatment landscape for multiple myeloma (MM) is rapidly evolving. This activity will examine tailored treatment approaches for patients with relapsed/refractory multiple myeloma. ...

  • Online Presentation Online Presentation

Updates on Molecular Testing in NSCLC

Oncologists have new options when treating advanced NSCLC. The use of molecular profiling to define subgroups of patients most likely to experience clinical benefit from novel targeted therapies has been endorsed by both ASCO and the National Comprehensive Cancer Network (NCCN).This activity will examine the role of molecular biomarkers in patients with advanced NSCLC. ...

  • Mobile + Online on QuantiaMD Mobile + Online on QuantiaMD

Patient-Centered Care in Advanced Prostate Cancer

Recommended treatment options for prostate cancer vary based on disease severity and life expectancy, with traditional approaches including active surveillance, surgery, radiation therapy, chemotherapy, and androgen deprivation therapy (ADT). Prostate cancer that progresses despite ADT is known as castration-resistant prostate cancer (CRPC). Until recently, the standard of care for CRPC patients w ...

  • Mobile + Online on QuantiaMD

Expired Programs

Targeting B-Cell Lymphomas: The Latest Updates in Therapies, Practice Strategies, and Clinical Research

The standards of care in treatment for non-Hodgkin lymphomas (NHL) are evolving as new therapies receive FDA approval and new evidence provides insight into optimal evidence-based approaches. Several key cellular pathways that drive malignant B-cell development have recently been identified and validated, leading to the development of therapies targeting these pathways. Agents targeting the B-cell ...

  • Online Presentation
Main Menu